|
|
|
| Effect of Ticagrelor on four items of thrombi and platelet function in elderly patients with acute coronary syndrome after complex percutaneous coronary intervention |
| MO Xianwen1 SONG Renyi2 LIANG Leng1 LI Yanmei1 ZHU Jinyue1 QIN Yuanwen2 WU Chengjie2 QIN Ping1 |
1.Department of Medical Laboratory, Guidong People’s Hospital, Guangxi Zhuang Autonomous Region, Wuzhou 543001, China;
2.Department of Cardiovascular, Guidong People’s Hospital, Guangxi Zhuang Autonomous Region, Wuzhou 543001, China |
|
|
|
|
Abstract Objective To investigate the effect of Ticagrelor on four items of thrombi and platelet function in elderly patients with acute coronary syndrome (ACS) after complex percutaneous coronary intervention (PCI). Methods Sixty elderly patients with ACS treated by complex PCI in Guidong People’s Hospital, Guangxi Zhuang Autonomous Region, from January 2020 to December 2021 were selected for this study, and the patients were divided into control group (30 cases) and study group (30 cases) by random number table method. The patients were treated with conventional medication after complicated PCI, including the control group treating by Clopidogrel combined with Aspirin and the study group treating by Ticagrelor combined with Aspirin, and the duration of treatment in both groups was six months. The four items of thrombi and platelet function were compared between the two groups before medication and one month after medication, and the occurrence of adverse cardiovascular events in the two groups during six months after complex PCI was recorded. Results One month after medication, the levels of thrombin-antithrombin, thrombomodulin, tissue-type plasminogen activator- plasminogen activator inhibitor 1 complex, and plasmin- α2-plasmin inhibitor complex in the two groups were lower than those before medication, and those in the study group were lower than those in the control group (P＜0.05). One month after medication, the arachidonic acid inhibition rate, adenosine diphosphate inhibition rate, adenosine diphosphate induced fibrin clot intensity, and platelet reactivity index in the two groups were higher than those before medication, and those in the study group were higher than those in the control group (P＜0.05). Within six months of treatment, the total incidence of cardiovascular adverse events in the study group was lower than that in the control group (P＜0.05). Conclusion Ticagrelor combined with Aspirin has good anti-platelet effect in elderly ACS patients after complex PCI, which can improve platelet function and reduce the incidence of adverse cardiovascular events.
|
|
|
|
|
|
[1] Bergmark BA，Mathenge N，Merlini PA，et al. Acute coronary syndromes [J]. The Lancet，2022，399（10332）：1347-1358.
[2] Ibanez B，James S，Agewall S，et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation：The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology（ESC）[J]. Eur Heart J，2018，39（2）：119-177.
[3] Benetou DR，Andreou I，Varlamos C，et al. Tailoring dual ant- iplatelet therapy for the complex PCI patient：current status and perspectives [J]. Cardiovasc Drug Ther，2020，34：697- 706.
[4] 张珂瑞，李勇.冠心病患者经皮冠状动脉介入术后支架内再狭窄危险因素的研究进展[J].医学综述，2022，28（1）： 105-111.
[5] 张韬，赵仙先.微创冠状动脉旁路移植术序贯经皮冠状动脉介入治疗冠状动脉粥样硬化性心脏病患者疗效及对预后影响[J].创伤与急危重病医学，2021，9（6）：485- 487.
[6] Saito Y，Kobayashi Y. Update on antithrombotic therapy after percutaneous coronary intervention [J]. Intern Med，2020，59（3）：311-321.
[7] 金蔚涛，赵阳，张玉坤，等.冠心病合并颈动脉狭窄患者在双联抗血小板治疗期内行颈动脉内膜剥脱手术的安全性[J].中华医学杂志，2019，99（39）：3073-3076.
[8] 郝凌霄，朱广辉，程帅，等.替格瑞洛与氯吡格雷在急性心肌梗死患者经皮冠状动脉介入治疗中有效性和安全性的对比研究[J].实用心脑肺血管病杂志，2017，25（6）：50-53.
[9] Sanderson NC，Parker WAE，Storey RF. Ticagrelor：clinical development and future potential [J]. Rev Cardiovasc Med，2021，22（2）：373-394.
[10] 马铄，黄浩，韩虎魁，等.替格瑞洛应用于老年急性冠脉综合征直接经皮冠状动脉介入术后真实世界中的疗效研究[J].实用医院临床杂志，2021，18（3）：13-16.
[11] Wang D，Yang XH，Zhang JD，et al. Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syn- drome：a meta-analysis [J]. Bmc Cardiovasc Disor，2018，18（1）：1-7.
[12] 公锐，裘淼涵，李子琪，等.急性冠状动脉综合征患者植入生物涂层可降解支架与永久涂层药物洗脱支架临床结局比较：一项单中心真实世界研究[J].临床军医杂志，2021，49（10）：1070-1073，1078.
[13] 邱炜佳，平政，解亚楠，等.药物洗脱支架治疗糖尿病和多支血管病变的急性冠状动脉综合征患者临床研究[J].中华老年医学杂志，2020，39（6）：636-638.
[14] Bhatt DL，Lopes RD，Harrington RA. Diagnosis and treatment of acute coronary syndromes：a review [J]. JAMA，2022，327（7）：662-675.
[15] 李雪梅，韩建伦，刘亮.急性冠脉综合征患者PCI术后治疗效果的影响因素分析[J].海南医学，2021，32（7）：839-842.
[16] 刘娜，张薇.替格瑞洛对冠心病经皮冠脉介入术治疗患者血小板参数及凝血功能的影响[J].血栓与止血学，2022，28（4）：598-599.
[17] 王婧，张英强，徐艳娟，等.替格瑞洛治疗冠心病不稳定型心绞痛对人血浆脂蛋白相关磷脂酶A2及心功能的影响[J].河北医学，2021，27（7）：1227-1232.
[18] Kim BK，Hong SJ，Cho YH，et al. Effect of ticagrelor mono- therapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary synd- rome：the TICO randomized clinical trial [J]. JAMA，2020， 323（23）：2407-2416.
[19] 田峰，白晓梅，王桂东.替格瑞洛和氯吡格雷对老年急性ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗术后并发症及预后的影响[J].河北医学，2021，27（2）：313-317.
[20] 张承花，陈静波，李建文，等.替格瑞洛用于急性心肌梗死经皮冠状动脉介入围术期对冠状动脉血流和炎症反应及心肌酶谱的影响[J].中国医药，2021，16（5）：661- 665.
[21] 郭春华，赵淑兰，周秋杰，等.老年急性ST段抬高型心肌梗死患者左心室血栓形成的发生率、预测因素、治疗策略和预后研究[J].中国心血管杂志，2022，27（1）：38- 42.
[22] 崔玉梅，董蕾.血清白介素17、脂蛋白（a）水平与ST段抬高型心肌梗死患者经皮冠状动脉介入术后支架内血栓形成的关系研究[J].实用心脑肺血管病杂志，2022， 30（3）：12-16.
[23] 刘长城，方颖，韦华，等.弥漫性冠状动脉病变外科术后早期应用新型抗血小板药物替格瑞洛的疗效分析[J].中国医药，2021，16（2）：213-216.
[24] 曲楠，郑春和.急性心肌梗死患者CCL2/CCR2与血小板聚集率的关系[J].心血管康复医学杂志，2018，27（6）：646-649.
[25] 解承娟，李满桂，任啟霞，等.血栓前标志物TAT、PIC、TM、tPAIC在脑血栓中检测的价值[J].医学临床研究，2019，36（2）：370-371，372.
[26] Watanabe-Kusunoki K，Nakazawa D，Ishizu A，et al. Throm- bomodulin as a physiological modulator of intravascular injury [J]. Front Immunol，2020，11：575890.
[27] 王燕英，陈海荣，李名兰.血栓调节蛋白与老年急性冠脉综合征病人PCI术后主要心血管不良事件的相关性探讨[J].实用老年医学，2020，34（1）：38-41.
[28] 陈倩.抗Xa活性检测在监测口服抗凝药利伐沙班及指导低分子肝素在PCI术中给药方案应用的研究和TM、TAT、PIC、tPAI-C的测定性能研究[D].北京：北京协和医学院，2021.
[29] 班素芬，李广华.危重血栓性疾病诊断中凝血标志物与炎性因子的研究[J].血栓与止血学，2019，25（3）：363- 366. |
|
|
|
